Skip to main content
main-content

Type 2 diabetes and clinical trials

Expert opinion editorial

The CAROLINA trial: Make or break for sulfonylureas?

Sulfonylurea pill

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas. 

Get more on: Sulfonylureas | DPP-4 inhibitors | Other diabetes medications

Expert opinion editorial

Are we using the right tests to diagnose diabetic neuropathy?

Diabetic foot test (symbolic image with models)

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy [read more].

Get more on: Diabetic neuropathy | Management of diabetic foot | Other diabetic complications

Journal article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Woman measuring her waist (symbolic image with model)

This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly among adults with obesity and without diabetes [read more].
Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Get more on:  Medication | Obesity | Type 2 diabetes

Journal article

Long-term effect of the color record method in self-monitoring of blood glucose on metabolic parameters in type 2 diabetes: A 2-year follow-up of the Color IMPACT study

Paper ECG

This article evaluates the potential long-term effect of two different color indication methods for self-monitoring of blood glucose on metabolic parameters in insulin-treated type 2 diabetes [read more].
Nishimura A et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0457-6

Get more on:  Devices and technology | Type 2 diabetes

Expert opinion editorial

Real-world evidence: Complementing clinical trials in type 2 diabetes

John Wilding

Editorial Board member John Wilding examines what real-world data means to today’s clinicians and presents his vision for the future of this type of evidence [read more].

Get more on: Type 2 diabetes | Clinical trials | Expert opinion

Expert opinion: Podcast

UK nutrition guidelines: A fresh approach

Pamela Dyson PhD RD and John Wilding DM FRCP

Board members Pamela Dyson and John Wilding talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines [listen to the podcast 9:43].

Get more on: Type 2 diabetes | Obesity | Diabetes preventionDiet and nutritional management 

Expert opinion editorial

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

Pill in hand (symbolic image with model)

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment [read more].

Get more on: Medication | Older adults |  Type 2 diabetes

Expert opinion editorial

Metformin: What is new with this old medication?

medication capsule

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded [read more].

Get more on: Type 2 diabetes | MetforminMedications | Expert opinion

medwireNews

10-05-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

10-05-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

09-25-2018 | Hypertension | News

Reweighting simulation may reconcile SPRINT, ACCORD BP findings

Research suggests that giving patients with type 2 diabetes intensive blood pressure treatment as per the ACCORD BP study would be beneficial in a real-world US population.

Journal articles and book chapters

11-03-2018 | Liraglutide (T2DM) | Article

Liraglutide and glycemic outcomes in the LEADER trial

Zinman B et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0524-z

08-26-2018 | Cardiovascular disorders | Article

Effects of aspirin for primary prevention in persons with diabetes mellitus

The ASCEND Study Collaborative Group. N Eng J Med 2018. doi:  10.1056/NEJMoa1804988

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits